ENG (Endoglin)

P=N/A, N=43, Completed, CHU de Reims | Recruiting --> Completed | N=20 --> 43 | Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Dec 2025

EVs enriched in platelet (CD49e) and endothelial (CD31) markers were associated with corticosteroid response, whereas EVs enriched with endothelial (CD105 and CD146) and B lymphocyte (CD19) markers were associated with mortality. Overall, EVs enriched in endothelial and monocyte markers may represent a candidate non-invasive tool for predicting corticosteroid response and mortality in AH, aiding risk stratification and early identification of non-responders for timely transplant evaluation.

The gap between pre‑clinical findings and clinical applications highlights the need for further investigation. Extensive research is still required to elucidate how therapeutic interventions achieve efficacy, ensure safety, and identify optimal strategies for targeting different organs in combination with other pharmacological agents.

TRC105 (carotuximab), a monoclonal antibody against endoglin, progressed through multiple clinical trials and was well tolerated, yet outcomes were disappointing, revealing a gap between preclinical findings and patient benefit...Future progress requires a deeper mechanistic resolution of endoglin's roles across tumor type and disease stage, along with the development of biomarkers incorporating spatial expression patterns. Successful translation will depend on matching endoglin-targeted therapy to patients and tumor ecosystems most likely to benefit, shifting from broad anti-angiogenic application to precision stromal targeting.

Immunohistochemical analysis further validated heterogeneous CD105 expression in tumor neovasculature and demonstrated a positive correlation between CD105 expression levels and PET-derived tumor uptake. Overall, 68Ga-DOTA-CDP shows promise as a peptide-based PET tracer for noninvasive tumor angiogenesis imaging.

P=N/A, N=6, Not yet recruiting, Beijing Stomatological Hospital , Capital Medical University; Beijing Stomatological Hospital , Capital Medical University

This study comprehensively characterized the molecular features of BCSCs through multi-omics approaches, identified reliable surface markers and key regulatory genes, and constructed a prognostic prediction model with clinical application value.

Despite the small sample size and absence of functional experiments, our results suggest that Pazopanib promotes cytotoxic immune programs but, by six months, reprograms PLT-EVs towards different adhesion characteristics contributing to Treg and MDSC expansion while suppressing NK activity. PLT-EVs may influence the balance between immune activation and suppression during anti-angiogenic therapy, suggesting PLT-EVs as biomarkers and therapeutic targets in mRCC.

This novel discovery sheds light on the molecular basis of plexiform lesion development in this rare case of combined PAH and HHT, highlighting a potential role of somatic mutations in driving endothelial cell proliferation in plexiform lesions.

Pretreatment endothelial-centric and inflammatory biomarkers outperformed both clinical and CMR measures in predicting CTRCD during chemotherapy.

We also find that THSD7A induces filopodia formation through activation of the Rho GTPase, Cdc42. These findings suggest a new model for filopodia formation, triggered by exosomes carrying THSD7A.

This work discovered the precise epigenetic mechanism involving histone methylation responsible for such changes in MSC phenotype. By inhibiting the histone methylation by GSK343, this study showed that MSC phenotype can be maintained over serial passaging as demonstrated by microscopy, multi-omics, and in vitro functional assays.